focus -WSS

focus

author：fashion 2025-08-19 20:44:51 - browse：365

Adobe

WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American companies, including in the biotech sector. Chinese biotechnology companies, the thinking goes, could threaten national security by giving the Chinese government access to the genetic and health information of Americans.

Just Wednesday, President Biden issued an executive order aimed at keeping sensitive data, including Americans’ genetic information, out of the hands of adversaries.

But American biotech companies worry they could become collateral damage if the government sloppily targets sanctions. They’re pushing back against legislation that would bar biotech companies from working with some Chinese companies, especially as the government takes aim at WuXi, a Chinese company considered a crucial partner for discovering, testing, and making medicines that has worked with such brands as Pfizer, AstraZeneca, and GSK.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

hotspot

knowledge

WSS

For Medicare Advantage, Democrats want stronger protections around AI

What would happen to your eyes if you looked at the solar eclipse?

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Gene therapy has helped boys walk. Can scientists keep it that way?

New guidelines on severe brain injury complicate already difficult decisions

Weight bias in eating disorder treatment complicated by new weight loss drugs

leisure time

focus

hotspot

What does generative AI mean for health care? We asked experts

To avoid data mishandling cases, universities eye AI and other tools

Tori Bowie and the unacceptable rates of Black maternal death

The battle over the Brookhaven Landfill on Long Island

Alkermes shareholders re

Readout LOUD podcast: How biotech is using artificial intelligence

Supreme Court strikes down use of affirmative action

The battle over the Brookhaven Landfill on Long Island

Duchenne breakthrough therapy leaves behind pioneering families

What we’ve learned from the Aduhelm mess

knowledge

Private equity deals in Medicare Advantage declines

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

In areas with more Black doctors, Black people live longer

CDC concerned about possible undetected monkeypox spread in U.K.

Cloning humans is technically possible. It's curious no one has tried

3 hurdles to bringing medical devices to the U.S. market

hotspot

hotspot

knowledge

hotspot